MimiVax and UI Pharmaceuticals Reach Significant Milestone in SurVaxM Manufacturing for Glioblastoma Therapy

  • SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facility
  • UI Pharmaceuticals is looking forward to supporting the need for larger clinical and commercial lots
  • MimiVax is utilizing SurVaxM in a Randomized Phase 2b clinical trial of glioblastoma

BUFFALO, N.Y., Jan. 10, 2025 /PRNewswire/ -- MimiVax, Inc. and UI Pharmaceuticals are excited to share the successful clinical production of SurVaxM, an innovative immunotherapy vaccine aimed at treating Glioblastoma (GBM), at UIP's newly certified $26 million sterile manufacturing plant. This partnership merges MimiVax's cutting-edge research with UIP's specialized knowledge in formulation development and sterile manufacturing, paving the way for potentially groundbreaking treatments for patients.